This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Santini, D. Articles by Tonini, G. Search for Related Content PubMed PubMed Citation Articles by Santini, D. Articles by Tonini, G.

Pamidronate Induces Modifications of Circulating Angiogenetic Factors in Cancer Patients

Università Campus Bio-Medico, 00155 Rome, Italy

Purpose: Recently, new experimental data suggested that, besides inhibiting osteoclasts, bisphosphonate may also have an antitumor effect. Antiangionetetic activity is one of the possible mechanisms of anticancer activity attributed to bisphosphonates. The purpose of this study was to evaluate the modifications in angiogenic cytokines levels after pamidronate infusion.

Experimental Design: Twenty-five consecutive cancer patients with bone metastases treated monthly with disodium pamidronate infusion were evaluated prospectively for circulating levels of vascular endothelial growth factor (VEGF), -IFN, interleukin (IL)-6, and IL-8 at different time points: just before and after 1, 2, and 7 days after pamidronate infusion.

Results: Basal VEGF levels decreased significantly 1, 2, and 7 days after pamidronate infusion. -IFN and IL-6 levels increased 1 day after the infusion but rapidly decreased after 2 days. Moreover, our data showed a statistically significant negative correlation between VEGF and -IFN levels (P < 0.0001) and a positive correlation between VEGF and IL-8 (P = 0.04).

Conclusions: This study confirms that pamidronate could have antiangiogenic properties through a significant and lasting decrease of VEGF serum levels.

This article has been cited by other articles:

				E Amir, M Trinkaus, C E Simmons, G Dranitsaris, and M J Clemons Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer J. Clin. Pathol., May 1, 2009; 62(5): 474 - 476. [Abstract] [Full Text] [PDF]

				C. Melani, S. Sangaletti, F. M. Barazzetta, Z. Werb, and M. P. Colombo Amino-Biphosphonate Mediated MMP-9 Inhibition Breaks the Tumor-Bone Marrow Axis Responsible for Myeloid-Derived Suppressor Cell Expansion and Macrophage Infiltration in Tumor Stroma Cancer Res., December 1, 2007; 67(23): 11438 - 11446. [Abstract] [Full Text] [PDF]

				S.L. Ruggiero and S.J. Drew Osteonecrosis of the Jaws and Bisphosphonate Therapy Journal of Dental Research, November 1, 2007; 86(11): 1013 - 1021. [Abstract] [Full Text] [PDF]

				D. Santini, B. Vincenzi, S. Galluzzo, F. Battistoni, L. Rocci, O. Venditti, G. Schiavon, S. Angeletti, F. Uzzalli, M. Caraglia, et al. Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients Clin. Cancer Res., August 1, 2007; 13(15): 4482 - 4486. [Abstract] [Full Text] [PDF]

				S Chiandussi, M Biasotto, F Dore, F Cavalli, M. Cova, and R Di Lenarda Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac. Radiol., July 1, 2006; 35(4): 236 - 243. [Abstract] [Full Text] [PDF]

				M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer, March 1, 2006; 13(1): 7 - 26. [Abstract] [Full Text] [PDF]

				M. R. MARKIEWICZ, J. E. MARGARONE III, J. H. CAMPBELL, and A. AGUIRRE Bisphosphonate-associated osteonecrosis of the jaws: A review of current knowledge J Am Dent Assoc, December 1, 2005; 136(12): 1669 - 1674. [Abstract] [Full Text] [PDF]

				A. Angel-Moreno Maroto, E. Martinez-Quintana, L. Suarez-Castellano, and J.-L. Perez-Arellano Painful hypertrophic osteoarthropathy successfully treated with octreotide. The pathogenetic role of vascular endothelial growth factor (VEGF) Rheumatology, October 1, 2005; 44(10): 1326 - 1327. [Full Text] [PDF]

				K. Takagi, M. Takagi, S. Kanangat, K. J. Warrington, H. Shigemitsu, and A. E. Postlethwaite Modulation of TNF-{alpha} Gene Expression by IFN-{gamma} and Pamidronate in Murine Macrophages: Regulation by STAT1-Dependent Pathways J. Immunol., February 15, 2005; 174(4): 1801 - 1810. [Abstract] [Full Text] [PDF]

				D. Santini, U. Vespasiani Gentilucci, B. Vincenzi, A. Picardi, F. Vasaturo, A. La Cesa, N. Onori, S. Scarpa, and G. Tonini The antineoplastic role of bisphosphonates: from basic research to clinical evidence Ann. Onc., October 1, 2003; 14(10): 1468 - 1476. [Abstract] [Full Text] [PDF]

				D. Santini, B. Vincenzi, G. Dicuonzo, G. Avvisati, C. Massacesi, F. Battistoni, M. Gavasci, L. Rocci, M. C. Tirindelli, V. Altomare, et al. Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients Clin. Cancer Res., August 1, 2003; 9(8): 2893 - 2897. [Abstract] [Full Text] [PDF]

				M. Wilhelm, V. Kunzmann, S. Eckstein, P. Reimer, F. Weissinger, T. Ruediger, and H.-P. Tony {gamma}{delta} T cells for immune therapy of patients with lymphoid malignancies Blood, July 1, 2003; 102(1): 200 - 206. [Abstract] [Full Text] [PDF]

				B. Vincenzi, D. Santini, L. Rocci, and G. Tonini Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann. Onc., May 1, 2003; 14(5): 806 - 807. [Full Text] [PDF]

				P. Fournier, S. Boissier, S. Filleur, J. Guglielmi, F. Cabon, M. Colombel, and P. Clezardin Bisphosphonates Inhibit Angiogenesis in Vitro and Testosterone-stimulated Vascular Regrowth in the Ventral Prostate in Castrated Rats Cancer Res., November 15, 2002; 62(22): 6538 - 6544. [Abstract] [Full Text] [PDF]